| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | extracellular matrix structural constituent conferring tensile strength | 3.01e-07 | 46 | 25 | 4 | GO:0030020 | |
| GeneOntologyMolecularFunction | endopeptidase activity | 7.03e-07 | 430 | 25 | 7 | GO:0004175 | |
| GeneOntologyMolecularFunction | structural molecule activity | 8.36e-06 | 891 | 25 | 8 | GO:0005198 | |
| GeneOntologyMolecularFunction | peptidase activity | 1.12e-05 | 654 | 25 | 7 | GO:0008233 | |
| GeneOntologyMolecularFunction | aspartic-type endopeptidase activity | 1.31e-05 | 37 | 25 | 3 | GO:0004190 | |
| GeneOntologyMolecularFunction | aspartic-type peptidase activity | 1.42e-05 | 38 | 25 | 3 | GO:0070001 | |
| GeneOntologyMolecularFunction | RNA-DNA hybrid ribonuclease activity | 8.22e-05 | 11 | 25 | 2 | GO:0004523 | |
| GeneOntologyMolecularFunction | extracellular matrix structural constituent | 8.25e-05 | 188 | 25 | 4 | GO:0005201 | |
| GeneOntologyMolecularFunction | serine-type endopeptidase activity | 8.59e-05 | 190 | 25 | 4 | GO:0004252 | |
| GeneOntologyMolecularFunction | serine-type peptidase activity | 1.20e-04 | 207 | 25 | 4 | GO:0008236 | |
| GeneOntologyMolecularFunction | serine hydrolase activity | 1.31e-04 | 212 | 25 | 4 | GO:0017171 | |
| GeneOntologyMolecularFunction | RNA-directed DNA polymerase activity | 1.36e-04 | 14 | 25 | 2 | GO:0003964 | |
| GeneOntologyMolecularFunction | RNA stem-loop binding | 3.11e-04 | 21 | 25 | 2 | GO:0035613 | |
| GeneOntologyMolecularFunction | nucleotidyltransferase activity | 8.80e-04 | 152 | 25 | 3 | GO:0016779 | |
| GeneOntologyMolecularFunction | RNA endonuclease activity, producing 5'-phosphomonoesters | 9.76e-04 | 37 | 25 | 2 | GO:0016891 | |
| GeneOntologyMolecularFunction | DNA polymerase activity | 1.03e-03 | 38 | 25 | 2 | GO:0034061 | |
| GeneOntologyMolecularFunction | endonuclease activity, active with either ribo- or deoxyribonucleic acids and producing 5'-phosphomonoesters | 1.51e-03 | 46 | 25 | 2 | GO:0016893 | |
| GeneOntologyMolecularFunction | RNA endonuclease activity | 4.37e-03 | 79 | 25 | 2 | GO:0004521 | |
| GeneOntologyMolecularFunction | zinc ion binding | 4.41e-03 | 891 | 25 | 5 | GO:0008270 | |
| GeneOntologyCellularComponent | collagen trimer | 5.86e-08 | 88 | 25 | 5 | GO:0005581 | |
| GeneOntologyCellularComponent | complex of collagen trimers | 1.98e-06 | 21 | 25 | 3 | GO:0098644 | |
| GeneOntologyCellularComponent | collagen-containing extracellular matrix | 3.38e-03 | 530 | 25 | 4 | GO:0062023 | |
| GeneOntologyCellularComponent | endoplasmic reticulum lumen | 7.05e-03 | 332 | 25 | 3 | GO:0005788 | |
| GeneOntologyCellularComponent | extracellular matrix | 7.19e-03 | 656 | 25 | 4 | GO:0031012 | |
| GeneOntologyCellularComponent | external encapsulating structure | 7.27e-03 | 658 | 25 | 4 | GO:0030312 | |
| GeneOntologyCellularComponent | basement membrane | 9.28e-03 | 122 | 25 | 2 | GO:0005604 | |
| Domain | Collagen | 4.29e-08 | 85 | 22 | 5 | PF01391 | |
| Domain | Collagen | 4.29e-08 | 85 | 22 | 5 | IPR008160 | |
| Domain | TRYPSIN_SER | 3.45e-06 | 90 | 22 | 4 | IPR033116 | |
| Domain | TRYPSIN_HIS | 5.91e-06 | 103 | 22 | 4 | IPR018114 | |
| Domain | TRYPSIN_SER | 6.63e-06 | 106 | 22 | 4 | PS00135 | |
| Domain | TRYPSIN_HIS | 6.88e-06 | 107 | 22 | 4 | PS00134 | |
| Domain | Peptidase_S1A | 8.54e-06 | 113 | 22 | 4 | IPR001314 | |
| Domain | TRYPSIN_DOM | 9.16e-06 | 115 | 22 | 4 | PS50240 | |
| Domain | Tryp_SPc | 9.81e-06 | 117 | 22 | 4 | SM00020 | |
| Domain | Trypsin | 1.12e-05 | 121 | 22 | 4 | PF00089 | |
| Domain | Trypsin_dom | 1.12e-05 | 121 | 22 | 4 | IPR001254 | |
| Domain | Peptidase_S1_PA | 1.20e-05 | 123 | 22 | 4 | IPR009003 | |
| Domain | C1Q | 6.43e-04 | 32 | 22 | 2 | SM00110 | |
| Domain | C1q | 6.43e-04 | 32 | 22 | 2 | PF00386 | |
| Domain | C1q_dom | 7.26e-04 | 34 | 22 | 2 | IPR001073 | |
| Domain | C1Q | 7.26e-04 | 34 | 22 | 2 | PS50871 | |
| Domain | - | 1.57e-03 | 50 | 22 | 2 | 2.60.120.40 | |
| Domain | Tumour_necrosis_fac-like_dom | 2.10e-03 | 58 | 22 | 2 | IPR008983 | |
| Pathway | REACTOME_COLLAGEN_CHAIN_TRIMERIZATION | 1.54e-05 | 44 | 16 | 3 | M27812 | |
| Pathway | REACTOME_ASSEMBLY_OF_COLLAGEN_FIBRILS_AND_OTHER_MULTIMERIC_STRUCTURES | 4.15e-05 | 61 | 16 | 3 | M27103 | |
| Pathway | REACTOME_COLLAGEN_BIOSYNTHESIS_AND_MODIFYING_ENZYMES | 5.50e-05 | 67 | 16 | 3 | M26999 | |
| Pathway | REACTOME_ANCHORING_FIBRIL_FORMATION | 1.26e-04 | 15 | 16 | 2 | M27161 | |
| Pathway | REACTOME_COLLAGEN_FORMATION | 1.33e-04 | 90 | 16 | 3 | M631 | |
| Pathway | REACTOME_DEGRADATION_OF_THE_EXTRACELLULAR_MATRIX | 2.67e-04 | 114 | 16 | 3 | MM14571 | |
| Pathway | REACTOME_EXTRACELLULAR_MATRIX_ORGANIZATION | 2.99e-04 | 300 | 16 | 4 | M610 | |
| Pathway | BIOCARTA_INTRINSIC_PATHWAY | 3.01e-04 | 23 | 16 | 2 | M15997 | |
| Pathway | BIOCARTA_INTRINSIC_PATHWAY | 3.01e-04 | 23 | 16 | 2 | MM1427 | |
| Pathway | REACTOME_DEGRADATION_OF_THE_EXTRACELLULAR_MATRIX | 4.88e-04 | 140 | 16 | 3 | M587 | |
| Pathway | REACTOME_LAMININ_INTERACTIONS | 5.16e-04 | 30 | 16 | 2 | M27216 | |
| Pathway | REACTOME_COLLAGEN_CHAIN_TRIMERIZATION | 9.65e-04 | 41 | 16 | 2 | MM15538 | |
| Pathway | PID_SYNDECAN_1_PATHWAY | 1.21e-03 | 46 | 16 | 2 | M198 | |
| Pathway | REACTOME_ASSEMBLY_OF_COLLAGEN_FIBRILS_AND_OTHER_MULTIMERIC_STRUCTURES | 1.43e-03 | 50 | 16 | 2 | MM14796 | |
| Pathway | REACTOME_COLLAGEN_DEGRADATION | 1.61e-03 | 53 | 16 | 2 | MM14566 | |
| Pathway | WP_COMPLEMENT_AND_COAGULATION_CASCADES | 1.92e-03 | 58 | 16 | 2 | M39649 | |
| Pathway | WP_DENGUE2_INTERACTIONS_WITH_COMPLEMENT_AND_COAGULATION_CASCADES | 1.99e-03 | 59 | 16 | 2 | M48343 | |
| Pathway | REACTOME_COLLAGEN_BIOSYNTHESIS_AND_MODIFYING_ENZYMES | 2.13e-03 | 61 | 16 | 2 | MM14637 | |
| Pathway | REACTOME_COLLAGEN_DEGRADATION | 2.34e-03 | 64 | 16 | 2 | M26953 | |
| Pathway | PID_INTEGRIN1_PATHWAY | 2.48e-03 | 66 | 16 | 2 | M18 | |
| Pathway | KEGG_COMPLEMENT_AND_COAGULATION_CASCADES | 2.71e-03 | 69 | 16 | 2 | M16894 | |
| Pathway | REACTOME_EXTRACELLULAR_MATRIX_ORGANIZATION | 2.84e-03 | 258 | 16 | 3 | MM14572 | |
| Pathway | WP_MECP2_AND_ASSOCIATED_RETT_SYNDROME | 3.03e-03 | 73 | 16 | 2 | M39401 | |
| Pathway | PID_AVB3_INTEGRIN_PATHWAY | 3.11e-03 | 74 | 16 | 2 | M160 | |
| Pathway | REACTOME_COLLAGEN_FORMATION | 3.28e-03 | 76 | 16 | 2 | MM14573 | |
| Pathway | REACTOME_INTEGRIN_CELL_SURFACE_INTERACTIONS | 3.28e-03 | 76 | 16 | 2 | MM14867 | |
| Pathway | REACTOME_INTEGRIN_CELL_SURFACE_INTERACTIONS | 4.08e-03 | 85 | 16 | 2 | M16441 | |
| Pubmed | Many human endogenous retrovirus K (HERV-K) proviruses are unique to humans. | 1.31e-09 | 4 | 25 | 3 | 10469592 | |
| Pubmed | 4.96e-07 | 2 | 25 | 2 | 17544811 | ||
| Pubmed | A revised nomenclature for transcribed human endogenous retroviral loci. | 6.06e-07 | 94 | 25 | 4 | 21542922 | |
| Pubmed | 1.49e-06 | 3 | 25 | 2 | 10837119 | ||
| Pubmed | 2.97e-06 | 4 | 25 | 2 | 7983737 | ||
| Pubmed | Transcriptionally active HERV-K genes: identification, isolation, and chromosomal mapping. | 4.95e-06 | 5 | 25 | 2 | 11401426 | |
| Pubmed | 7.08e-06 | 52 | 25 | 3 | 22219177 | ||
| Pubmed | Proteomic characterization of human multiple myeloma bone marrow extracellular matrix. | 1.21e-05 | 62 | 25 | 3 | 28344315 | |
| Pubmed | 1.39e-05 | 8 | 25 | 2 | 25261715 | ||
| Pubmed | Early molecular events during retinoic acid induced differentiation of neuromesodermal progenitors. | 3.26e-05 | 12 | 25 | 2 | 27793834 | |
| Pubmed | 3.85e-05 | 13 | 25 | 2 | 25775517 | ||
| Pubmed | A Second Heart Field-Derived Vasculogenic Niche Contributes to Cardiac Lymphatics. | 3.85e-05 | 13 | 25 | 2 | 31928974 | |
| Pubmed | 6.70e-05 | 17 | 25 | 2 | 15242798 | ||
| Pubmed | 7.54e-05 | 18 | 25 | 2 | 18664271 | ||
| Pubmed | Proteostasis is essential during cochlear development for neuron survival and hair cell polarity. | 8.42e-05 | 19 | 25 | 2 | 31321879 | |
| Pubmed | Dysregulation of sonic hedgehog signaling causes hearing loss in ciliopathy mouse models. | 9.35e-05 | 20 | 25 | 2 | 33382037 | |
| Pubmed | 9.35e-05 | 20 | 25 | 2 | 17067568 | ||
| Pubmed | 1.03e-04 | 21 | 25 | 2 | 27856617 | ||
| Pubmed | 1.85e-04 | 28 | 25 | 2 | 17126317 | ||
| Pubmed | 2.13e-04 | 30 | 25 | 2 | 16368932 | ||
| Pubmed | 2.65e-04 | 175 | 25 | 3 | 28071719 | ||
| Pubmed | 3.08e-04 | 36 | 25 | 2 | 19411759 | ||
| Pubmed | PRC1 sustains the integrity of neural fate in the absence of PRC2 function. | 3.43e-04 | 38 | 25 | 2 | 34994686 | |
| Pubmed | 3.98e-04 | 493 | 25 | 4 | 15368895 | ||
| Pubmed | A Dynamic Splicing Program Ensures Proper Synaptic Connections in the Developing Cerebellum. | 4.61e-04 | 44 | 25 | 2 | 32492419 | |
| Pubmed | Activin A Determines Steroid Levels and Composition in the Fetal Testis. | 5.26e-04 | 47 | 25 | 2 | 32274496 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr15q21 | 4.18e-03 | 177 | 25 | 2 | chr15q21 | |
| GeneFamily | Collagens | 8.43e-06 | 46 | 16 | 3 | 490 | |
| GeneFamily | Endogenous ligands|C1q and TNF related | 1.11e-04 | 18 | 16 | 2 | 1372 | |
| GeneFamily | Proteases, serine | 1.39e-03 | 63 | 16 | 2 | 738 | |
| Coexpression | NABA_COLLAGENS | 5.36e-06 | 43 | 21 | 3 | MM17060 | |
| Coexpression | NABA_COLLAGENS | 5.75e-06 | 44 | 21 | 3 | M3005 | |
| Coexpression | NABA_MATRISOME | 8.82e-06 | 1008 | 21 | 7 | MM17056 | |
| Coexpression | NABA_MATRISOME | 9.91e-06 | 1026 | 21 | 7 | M5889 | |
| Coexpression | URS_ADIPOCYTE_DIFFERENTIATION_UP | 1.96e-05 | 66 | 21 | 3 | M15476 | |
| Coexpression | NABA_CORE_MATRISOME | 5.74e-05 | 270 | 21 | 4 | MM17057 | |
| Coexpression | NABA_CORE_MATRISOME | 6.16e-05 | 275 | 21 | 4 | M5884 | |
| Coexpression | FOROUTAN_INTEGRATED_TGFB_EMT_UP | 1.17e-04 | 120 | 21 | 3 | M42505 | |
| Coexpression | HEBERT_MATRISOME_TNBC_LUNG_METASTASIS | 1.53e-04 | 23 | 21 | 2 | M48001 | |
| Coexpression | LI_WILMS_TUMOR | 2.12e-04 | 27 | 21 | 2 | M10773 | |
| Coexpression | SIMBULAN_UV_RESPONSE_NORMAL_DN | 3.18e-04 | 33 | 21 | 2 | M16114 | |
| Coexpression | FOROUTAN_PRODRANK_TGFB_EMT_UP | 4.19e-04 | 185 | 21 | 3 | M42503 | |
| Coexpression | FOROUTAN_TGFB_EMT_UP | 4.67e-04 | 192 | 21 | 3 | M42501 | |
| Coexpression | GSE26290_CTRL_VS_AKT_INHIBITOR_TREATED_ANTI_CD3_AND_IL2_STIM_CD8_TCELL_UP | 4.96e-04 | 196 | 21 | 3 | M8135 | |
| Coexpression | GSE16386_IL4_VS_IL4_AND_ROSIGLITAZONE_STIM_MACROPHAGE_6H_DN | 5.11e-04 | 198 | 21 | 3 | M7916 | |
| Coexpression | GSE360_L_MAJOR_VS_T_GONDII_DC_UP | 5.11e-04 | 198 | 21 | 3 | M5207 | |
| Coexpression | GSE14308_TH2_VS_NATURAL_TREG_UP | 5.18e-04 | 199 | 21 | 3 | M3368 | |
| Coexpression | GSE17721_POLYIC_VS_CPG_8H_BMDC_DN | 5.18e-04 | 199 | 21 | 3 | M3947 | |
| Coexpression | GSE360_L_MAJOR_VS_M_TUBERCULOSIS_DC_UP | 5.18e-04 | 199 | 21 | 3 | M5213 | |
| Coexpression | GSE15324_NAIVE_VS_ACTIVATED_CD8_TCELL_UP | 5.26e-04 | 200 | 21 | 3 | M3523 | |
| Coexpression | GSE16385_MONOCYTE_VS_MACROPHAGE_DN | 5.26e-04 | 200 | 21 | 3 | M7901 | |
| Coexpression | GSE557_WT_VS_CIITA_KO_DC_DN | 5.26e-04 | 200 | 21 | 3 | M6008 | |
| ToppCell | PND01-03-samps-Mesenchymal-Myofibroblast|PND01-03-samps / Age Group, Lineage, Cell class and subclass | 1.47e-06 | 182 | 21 | 4 | 812dac35b9aa05be48258082e007f6c00e7b4dd8 | |
| ToppCell | PCW_05-06-Mesenchymal-Mesenchymal_fibroblastic-mes_immature_adventitial_fibro_(9)|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung | 1.60e-06 | 186 | 21 | 4 | 8915436d09775f2828a7678af203b1082b36e21c | |
| ToppCell | PCW_05-06-Mesenchymal-Mesenchymal_fibroblastic-mes_adventitial_fibro_(10)|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung | 1.78e-06 | 191 | 21 | 4 | 156b467187331ac6ca390d6ca861d9670bb7b956 | |
| ToppCell | Neuron-Postmitotic-Excitatory_Neuron_-Newborn-22|World / Primary Cells by Cluster | 1.86e-06 | 193 | 21 | 4 | 3b927d4b8ecb21a408424ef91a23746c21741f49 | |
| ToppCell | E12.5-Mesenchymal-mesenchymal_fibroblast-mesenchymal_alveolar_niche_cell|E12.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 1.93e-06 | 195 | 21 | 4 | febe746099964b9ea9e75f2efc72c962c01f0421 | |
| ToppCell | 3'-Pediatric_IBD-SmallIntestine-Mesenchymal-fibroblastic-Stromal_4_(MMP1+)|Pediatric_IBD / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 2.05e-06 | 198 | 21 | 4 | 229588189825b1080181db9515185677b742c668 | |
| ToppCell | severe_COVID-19-cDC|World / disease group, cell group and cell class (v2) | 5.19e-05 | 156 | 21 | 3 | 0a7e18ed8e13261c405eb6b9a183e99d8e1aac37 | |
| ToppCell | severe_COVID-19-cDC|severe_COVID-19 / disease group, cell group and cell class (v2) | 5.29e-05 | 157 | 21 | 3 | ec1978e07e2214048d015d8bb793c1d9991f6e37 | |
| ToppCell | 3'-GW_trimst-1.5-LargeIntestine-Mesenchymal-stromal_related-ICC|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 5.71e-05 | 161 | 21 | 3 | deb10628d258fb813c293f81fb71be8e383dc82a | |
| ToppCell | 3'-GW_trimst-1.5-LargeIntestine-Mesenchymal-stromal_related|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 5.71e-05 | 161 | 21 | 3 | 8aaca49b53a551395f4025ac4e535c7b0ce41a49 | |
| ToppCell | droplet-Pancreas-Exocrine-24m-Epithelial-pancreatic_acinar_cell|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.14e-05 | 165 | 21 | 3 | 622aca1d49bd8c917b131e4f4959d9dba411d22b | |
| ToppCell | facs-Brain_Myeloid-Hippocampus-24m-Myeloid-nan|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.36e-05 | 167 | 21 | 3 | a21a2b301d0a3d7a41e605f7a3c37548962a331d | |
| ToppCell | facs-Brain_Myeloid-Hippocampus-24m|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.36e-05 | 167 | 21 | 3 | 0e746483773bde6582874a33591ab2a578d724eb | |
| ToppCell | facs-Brain_Myeloid-Hippocampus-24m-Myeloid|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.36e-05 | 167 | 21 | 3 | 7f3224af9b30082b927a822b91f96e0c88151b4e | |
| ToppCell | droplet-Pancreas-Exocrine-24m-Epithelial-pancreatic_acinar_cell|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.36e-05 | 167 | 21 | 3 | 3c06894fc6177f3c204094719904da42f08b9af8 | |
| ToppCell | E15.5-Mesenchymal-mesenchymal_fibroblast-mesothelial_cell_of_visceral_pleura|E15.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 8.34e-05 | 183 | 21 | 3 | 274f274cf60daa30d6a4cd603a3af7823bfb8016 | |
| ToppCell | Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_1-Inh_L1_ADARB2_ADAM33|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 8.34e-05 | 183 | 21 | 3 | 5e361be3ae3fe05098968e58427630127bd12675 | |
| ToppCell | 15-Distal-Mesenchymal-Pericyte|Distal / Age, Tissue, Lineage and Cell class | 9.03e-05 | 188 | 21 | 3 | 4963382e54aac06bf5047c7d725393db70667ee7 | |
| ToppCell | facs-Lung-18m-Mesenchymal-fibroblast-adventitial_fibroblast-adventitial_fibroblast_l17|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 9.03e-05 | 188 | 21 | 3 | bba6b273bd47dd0e27fde914e9e6fc9d76fd5176 | |
| ToppCell | droplet-Lung-LUNG-1m-Mesenchymal-Adventitial_Fibroblast|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 9.18e-05 | 189 | 21 | 3 | 378f26f751ab4b470948c35dd8347de72dd12ff7 | |
| ToppCell | droplet-Lung-LUNG-1m-Mesenchymal-adventitial_cell|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 9.18e-05 | 189 | 21 | 3 | f0a2d4ef9896d764971ebbc6952510c128bb76e8 | |
| ToppCell | 15-Distal-Mesenchymal-Mesenchyme_SERPINF1-high|Distal / Age, Tissue, Lineage and Cell class | 9.32e-05 | 190 | 21 | 3 | b47472dc9fe6ed99c2365203a3d8a59879e74a70 | |
| ToppCell | E18.5-Mesenchymal-Mesenchymal_structural-Fibroblastic-AF2-AF2_mature|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 9.47e-05 | 191 | 21 | 3 | 75d2197076a9dfc868e8baf95bd4c5e44f438e3e | |
| ToppCell | droplet-Lung-1m-Mesenchymal-fibroblast-adventitial_fibroblast|1m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 9.62e-05 | 192 | 21 | 3 | f9fb24457999dc9e751a099d7f995543b9330ad4 | |
| ToppCell | PCW_07-8.5-Mesenchymal-Mesenchymal_fibroblastic-mes_adventitial_fibro_(10)|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung | 9.76e-05 | 193 | 21 | 3 | cd45118ced91b10baed3b1068d4673ec99824b86 | |
| ToppCell | PCW_13-14-Mesenchymal-Mesenchymal_fibroblastic-mes_adventitial_fibro_(10)|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung | 9.76e-05 | 193 | 21 | 3 | adc9fc94f9ec686a417d08c0b8b7b7ab687afec0 | |
| ToppCell | 18-Distal-Mesenchymal-Pericyte|Distal / Age, Tissue, Lineage and Cell class | 1.01e-04 | 195 | 21 | 3 | e0ee7905499ee1a1ca7b1184e2713028cf156985 | |
| ToppCell | (3)_Chondrocytes-(34)_Chondro-progen|World / Cell class and subclass of bone marrow stroma cells in homeostatis | 1.01e-04 | 195 | 21 | 3 | d00cb2fab25f2026a9668a7f0686938a2e7155e2 | |
| ToppCell | H1299-infected-SARSCoV2|infected / Cell line, Condition and Strain | 1.04e-04 | 197 | 21 | 3 | 0fa3e4cf93e77d78b1f97b906c5b13ca741ae17e | |
| ToppCell | myeloid-Dendritic_cell-Conventional_dendritic_cell|World / Lineage, cell class and subclass | 1.05e-04 | 198 | 21 | 3 | 2ec42643200aa9feb33e2b87570f276fbad21cad | |
| ToppCell | myeloid-Dendritic_cell|World / Lineage, cell class and subclass | 1.05e-04 | 198 | 21 | 3 | 240fff8264caeb7d1efcbccb187fe93744559bbc | |
| ToppCell | Brain_organoid-organoid_Velasco_nature-3_mon-Neuronal-CPNs|3_mon / Sample Type, Dataset, Time_group, and Cell type. | 1.05e-04 | 198 | 21 | 3 | 60d8d3bbd754ffde41c50013d822667b185a9751 | |
| ToppCell | (02)_MMP9/10+|World / shred by cell type by condition | 1.07e-04 | 199 | 21 | 3 | 3f78eddeaa67d3b767aa38de765632166b09a4f0 | |
| ToppCell | Neuronal-Excitatory-eA(LAMP5_LINC00507)-LTK--|Neuronal / cells hierarchy compared to all cells using T-Statistic | 1.08e-04 | 200 | 21 | 3 | 66e2f3e2e9063f17b47621120eb6009405f69e7e | |
| ToppCell | Fetal_brain-fetalBrain_Zhong_nature-GW16|fetalBrain_Zhong_nature / Sample Type, Dataset, Time_group, and Cell type. | 1.08e-04 | 200 | 21 | 3 | fd6b4ff4330db11c03f1eb4e06b43a162326f744 | |
| ToppCell | Fetal_brain-organoid_Tanaka_cellReport-GW16|organoid_Tanaka_cellReport / Sample Type, Dataset, Time_group, and Cell type. | 1.08e-04 | 200 | 21 | 3 | 8795920911ee75c09a97cc948c14ad7301b27796 | |
| ToppCell | Neuronal-Excitatory-eA(LAMP5_LINC00507)-LTK---L2|Neuronal / cells hierarchy compared to all cells using T-Statistic | 1.08e-04 | 200 | 21 | 3 | 6ebdae4438bc64c6620416f64a7e22fbca2664bf | |
| ToppCell | Neuronal-Excitatory-eA(LAMP5_LINC00507)-LTK|Neuronal / cells hierarchy compared to all cells using T-Statistic | 1.08e-04 | 200 | 21 | 3 | 940892bea41fde567f138a896d151acccef03a6a | |
| ToppCell | Neuronal-Excitatory-eA(LAMP5_LINC00507)-LTK-|Neuronal / cells hierarchy compared to all cells using T-Statistic | 1.08e-04 | 200 | 21 | 3 | 081ca331b56f85167acfc73af9d2e91f398f8c4d | |
| Drug | AC1L1C2F | 2.90e-06 | 110 | 21 | 4 | CID000001711 | |
| Drug | GK-101 | 4.73e-06 | 36 | 21 | 3 | CID000161853 | |
| Drug | Selara | 4.82e-06 | 125 | 21 | 4 | CID000150310 | |
| Drug | Madecassol | 1.00e-05 | 46 | 21 | 3 | CID000108062 | |
| Drug | d-indobufen | 1.29e-05 | 50 | 21 | 3 | CID000044562 | |
| Drug | L-lysyl-L-lysyl-L-lysine | 1.34e-05 | 162 | 21 | 4 | CID000072363 | |
| Drug | ridogrel | 1.45e-05 | 52 | 21 | 3 | CID005362391 | |
| Drug | NSC49633 | 1.54e-05 | 53 | 21 | 3 | CID000023340 | |
| Drug | LMWH | 2.23e-05 | 663 | 21 | 6 | CID000000772 | |
| Drug | AC1LAKND | 2.47e-05 | 62 | 21 | 3 | CID000470146 | |
| Drug | foscarnet | 2.52e-05 | 190 | 21 | 4 | CID000003414 | |
| Drug | Clioquinol [130-26-7]; Up 200; 13uM; MCF7; HT_HG-U133A | 2.57e-05 | 191 | 21 | 4 | 6461_UP | |
| Drug | Cinchonine [118-10-5]; Down 200; 13.6uM; PC3; HT_HG-U133A | 2.73e-05 | 194 | 21 | 4 | 3988_DN | |
| Drug | Hydralazine hydrochloride [304-20-1]; Up 200; 20.4uM; MCF7; HT_HG-U133A | 2.79e-05 | 195 | 21 | 4 | 4746_UP | |
| Drug | Mephenytoin [50-12-4]; Up 200; 18.4uM; HL60; HT_HG-U133A | 2.84e-05 | 196 | 21 | 4 | 6158_UP | |
| Drug | Phthalylsulfathiazole [85-73-4]; Up 200; 10uM; MCF7; HT_HG-U133A | 2.84e-05 | 196 | 21 | 4 | 3371_UP | |
| Drug | N-Acetyl-L-leucine [1188-21-2]; Up 200; 23uM; HL60; HT_HG-U133A | 2.90e-05 | 197 | 21 | 4 | 3085_UP | |
| Drug | Metoclopramide monohydrochloride [7232-21-5]; Up 200; 11.8uM; MCF7; HT_HG-U133A | 3.02e-05 | 199 | 21 | 4 | 3625_UP | |
| Drug | Fipexide hydrochloride [34161-23-4]; Up 200; 9.4uM; PC3; HT_HG-U133A | 3.08e-05 | 200 | 21 | 4 | 5737_UP | |
| Drug | 2f1b | 3.12e-05 | 67 | 21 | 3 | CID011963508 | |
| Drug | BAPN | 3.71e-05 | 71 | 21 | 3 | CID000001647 | |
| Drug | malotilate | 3.71e-05 | 71 | 21 | 3 | CID000004006 | |
| Drug | AC1NMZ1B | 4.38e-05 | 75 | 21 | 3 | CID005034185 | |
| Drug | strontium ranelate | 4.73e-05 | 77 | 21 | 3 | CID006918182 | |
| Drug | AC1Q6PCP | 5.30e-05 | 230 | 21 | 4 | CID000005267 | |
| Drug | 17-isoprogesterone | 5.72e-05 | 1170 | 21 | 7 | CID000004920 | |
| Drug | halofuginone lactate | 6.36e-05 | 85 | 21 | 3 | CID000062891 | |
| Drug | 4-hydroxyproline | 7.80e-05 | 91 | 21 | 3 | CID000000825 | |
| Drug | hyaluronan | 8.92e-05 | 263 | 21 | 4 | CID000024759 | |
| Drug | PG E | 1.09e-04 | 17 | 21 | 2 | CID000031217 | |
| Drug | ticlopidine | 1.13e-04 | 103 | 21 | 3 | CID000005472 | |
| Drug | hydroxylysine | 1.33e-04 | 109 | 21 | 3 | CID000001029 | |
| Drug | PPACK | 1.48e-04 | 113 | 21 | 3 | CID003036757 | |
| Drug | AC1L9732 | 1.52e-04 | 114 | 21 | 3 | CID000439300 | |
| Drug | Tranilast sodium | 1.56e-04 | 115 | 21 | 3 | CID000005527 | |
| Drug | AC1L1K15 | 1.77e-04 | 120 | 21 | 3 | CID000005293 | |
| Drug | diisopropylfluorophosphate | 1.92e-04 | 321 | 21 | 4 | CID000005936 | |
| Drug | AC1L18QD | 2.01e-04 | 325 | 21 | 4 | CID000000213 | |
| Drug | DMSe | 2.35e-04 | 132 | 21 | 3 | CID000020796 | |
| Drug | pirfenidone | 2.67e-04 | 138 | 21 | 3 | CID000040632 | |
| Drug | DL-penicillamine | 2.73e-04 | 139 | 21 | 3 | CID000004727 | |
| Drug | PCR 4099 | 2.73e-04 | 139 | 21 | 3 | CID000002806 | |
| Drug | AC1NRCR9 | 3.02e-04 | 28 | 21 | 2 | CID005289146 | |
| Drug | candesartan cilexetil | 3.09e-04 | 145 | 21 | 3 | CID000002540 | |
| Drug | benzamidine | 3.22e-04 | 147 | 21 | 3 | CID000002332 | |
| Drug | dodecanethiol | 4.20e-04 | 33 | 21 | 2 | CID000008195 | |
| Drug | 6-alpha-methylprednisolone hemisuccinate | 5.01e-04 | 36 | 21 | 2 | CID000001875 | |
| Drug | khellin | 5.01e-04 | 171 | 21 | 3 | CID000003828 | |
| Drug | seocalcitol | 5.18e-04 | 173 | 21 | 3 | ctd:C078903 | |
| Drug | Thonzonium bromide [553-08-2]; Up 200; 6.8uM; PC3; HT_HG-U133A | 5.18e-04 | 173 | 21 | 3 | 4617_UP | |
| Drug | AC1L1DD6 | 5.73e-04 | 179 | 21 | 3 | CID000002299 | |
| Drug | isocoumarin | 5.88e-04 | 39 | 21 | 2 | CID000068108 | |
| Drug | STOCK1N-35215; Up 200; 10uM; PC3; HT_HG-U133A | 6.01e-04 | 182 | 21 | 3 | 6427_UP | |
| Drug | p-fluorophenylalanine | 6.19e-04 | 40 | 21 | 2 | CID000004654 | |
| Drug | prochlorperazine dimaleate salt; Up 200; 10uM; PC3; HT_HG-U133A | 6.20e-04 | 184 | 21 | 3 | 4439_UP | |
| Drug | LY 294002; Up 200; 10uM; PC3; HT_HG-U133A | 6.40e-04 | 186 | 21 | 3 | 4463_UP | |
| Drug | 12(S)-hydroxyeicosatetraenoic acid | 6.71e-04 | 189 | 21 | 3 | CID000001413 | |
| Drug | Rolipram [61413-54-5]; Up 200; 14.6uM; HL60; HT_HG-U133A | 6.71e-04 | 189 | 21 | 3 | 3072_UP | |
| Drug | Gliquidone [33342-05-1]; Up 200; 7.6uM; PC3; HT_HG-U133A | 6.81e-04 | 190 | 21 | 3 | 7301_UP | |
| Drug | 17-AAG; Up 200; 1uM; PC3; HT_HG-U133A | 6.91e-04 | 191 | 21 | 3 | 4442_UP | |
| Drug | valinomycin; Down 200; 0.1uM; MCF7; HT_HG-U133A | 6.91e-04 | 191 | 21 | 3 | 5957_DN | |
| Drug | Aspartic acid, N-acetyl (R,S) [997-55-7]; Up 200; 22.8uM; MCF7; HT_HG-U133A | 7.13e-04 | 193 | 21 | 3 | 4125_UP | |
| Drug | Bromperidol [10457-90-6]; Up 200; 9.6uM; MCF7; HT_HG-U133A | 7.13e-04 | 193 | 21 | 3 | 2872_UP | |
| Drug | ethylnylestradiol | 7.22e-04 | 1251 | 21 | 6 | CID000003285 | |
| Drug | Carbetapentane citrate [23142-01-0]; Up 200; 7.6uM; MCF7; HT_HG-U133A | 7.23e-04 | 194 | 21 | 3 | 5610_UP | |
| Drug | Rapamycin; Down 200; 0.1uM; HL60; HT_HG-U133A | 7.23e-04 | 194 | 21 | 3 | 6201_DN | |
| Drug | Sulfanilamide [63-74-1]; Up 200; 23.2uM; PC3; HT_HG-U133A | 7.23e-04 | 194 | 21 | 3 | 4474_UP | |
| Drug | Equilin [474-86-2]; Down 200; 15uM; MCF7; HT_HG-U133A | 7.23e-04 | 194 | 21 | 3 | 5620_DN | |
| Drug | chlorpromazine hydrochloride; Up 200; 1uM; PC3; HT_HG-U133A | 7.23e-04 | 194 | 21 | 3 | 4441_UP | |
| Drug | Phenelzine sulfate [156-51-4]; Up 200; 17uM; MCF7; HT_HG-U133A | 7.23e-04 | 194 | 21 | 3 | 4360_UP | |
| Drug | Graveoline [485-61-0]; Up 200; 14.4uM; PC3; HT_HG-U133A | 7.23e-04 | 194 | 21 | 3 | 3716_UP | |
| Drug | estradiol; Down 200; 0.01uM; PC3; HT_HG-U133A | 7.34e-04 | 195 | 21 | 3 | 5910_DN | |
| Drug | Diethylstilbestrol [56-53-1]; Down 200; 15uM; MCF7; HT_HG-U133A | 7.34e-04 | 195 | 21 | 3 | 4369_DN | |
| Drug | Melatonin [73-31-4]; Up 200; 17.2uM; PC3; HT_HG-U133A | 7.34e-04 | 195 | 21 | 3 | 6293_UP | |
| Drug | Pempidine tartrate [546-48-5]; Up 200; 13uM; HL60; HT_HG-U133A | 7.34e-04 | 195 | 21 | 3 | 2172_UP | |
| Drug | Trimeprazine tartrate [4330-99-8]; Up 200; 5.4uM; HL60; HT_HG-U133A | 7.34e-04 | 195 | 21 | 3 | 2736_UP | |
| Drug | Pramoxine hydrochloride [637-58-1]; Up 200; 12.2uM; MCF7; HT_HG-U133A | 7.34e-04 | 195 | 21 | 3 | 4368_UP | |
| Drug | Diethylstilbestrol [56-53-1]; Down 200; 15uM; PC3; HT_HG-U133A | 7.34e-04 | 195 | 21 | 3 | 3812_DN | |
| Drug | Flutamide [13311-84-7]; Up 200; 14.4uM; MCF7; HT_HG-U133A | 7.45e-04 | 196 | 21 | 3 | 4361_UP | |
| Drug | Sulfamethoxazole [723-46-6]; Up 200; 15.8uM; HL60; HT_HG-U133A | 7.45e-04 | 196 | 21 | 3 | 2335_UP | |
| Drug | Enoxacin [74011-58-8]; Up 200; 12.4uM; MCF7; HT_HG-U133A | 7.45e-04 | 196 | 21 | 3 | 5251_UP | |
| Drug | Hymecromone [90-33-5]; Up 200; 22.8uM; PC3; HT_HG-U133A | 7.45e-04 | 196 | 21 | 3 | 4623_UP | |
| Drug | Betaxolol hydrochloride [63659-19-8]; Up 200; 11.6uM; MCF7; HT_HG-U133A | 7.45e-04 | 196 | 21 | 3 | 3208_UP | |
| Drug | D-cycloserine [68-41-7]; Up 200; 39.2uM; MCF7; HT_HG-U133A | 7.45e-04 | 196 | 21 | 3 | 6782_UP | |
| Drug | Piretanide [55837-27-9]; Up 200; 11uM; PC3; HT_HG-U133A | 7.45e-04 | 196 | 21 | 3 | 4490_UP | |
| Drug | Epicatechin-(-) [154-23-4]; Up 200; 13.8uM; MCF7; HT_HG-U133A | 7.45e-04 | 196 | 21 | 3 | 4419_UP | |
| Drug | Beta-sistosterol [83-46-5]; Up 200; 9.6uM; MCF7; HT_HG-U133A | 7.45e-04 | 196 | 21 | 3 | 4154_UP | |
| Drug | Cytisine (-) [485-35-8]; Up 200; 21uM; MCF7; HT_HG-U133A | 7.56e-04 | 197 | 21 | 3 | 2759_UP | |
| Drug | Procyclidine hydrochloride [1508-76-5]; Up 200; 12.4uM; HL60; HT_HG-U133A | 7.56e-04 | 197 | 21 | 3 | 2991_UP | |
| Drug | Benzethonium chloride [121-54-0]; Down 200; 9uM; MCF7; HT_HG-U133A | 7.56e-04 | 197 | 21 | 3 | 7207_DN | |
| Drug | CP-319743 [172078-87-4]; Down 200; 10uM; MCF7; HT_HG-U133A | 7.56e-04 | 197 | 21 | 3 | 7486_DN | |
| Drug | Methocarbamol [532-03-6]; Up 200; 16.6uM; MCF7; HT_HG-U133A | 7.56e-04 | 197 | 21 | 3 | 2274_UP | |
| Drug | Dimethisoquin hydrochloride [2773-92-4]; Up 200; 13uM; HL60; HT_HG-U133A | 7.56e-04 | 197 | 21 | 3 | 2151_UP | |
| Drug | Altretamine [654-05-6]; Down 200; 19uM; HL60; HT_HG-U133A | 7.56e-04 | 197 | 21 | 3 | 3090_DN | |
| Drug | Esculin Hydrate [531-75-9]; Up 200; 11.8uM; MCF7; HT_HG-U133A | 7.56e-04 | 197 | 21 | 3 | 3390_UP | |
| Drug | Chloroquine diphosphate [50-63-5]; Up 200; 7.8uM; MCF7; HT_HG-U133A | 7.56e-04 | 197 | 21 | 3 | 2869_UP | |
| Drug | Meclofenamic acid sodium salt monohydrate [6385-02-0]; Up 200; 11.8uM; MCF7; HT_HG-U133A | 7.56e-04 | 197 | 21 | 3 | 2291_UP | |
| Drug | Metolazone [17560-51-9]; Up 200; 11uM; MCF7; HT_HG-U133A | 7.56e-04 | 197 | 21 | 3 | 1514_UP | |
| Drug | Doxepin hydrochloride [1229-29-4]; Up 200; 12.6uM; HL60; HT_HG-U133A | 7.56e-04 | 197 | 21 | 3 | 2384_UP | |
| Drug | Piperidolate hydrochloride [129-77-1]; Up 200; 11.2uM; MCF7; HT_HG-U133A | 7.56e-04 | 197 | 21 | 3 | 3551_UP | |
| Disease | skin disease (implicated_via_orthology) | 1.45e-06 | 3 | 21 | 2 | DOID:37 (implicated_via_orthology) | |
| Disease | serum lipopolysaccharide activity | 1.01e-05 | 7 | 21 | 2 | EFO_0600064 | |
| Disease | Feeding difficulties | 7.33e-05 | 18 | 21 | 2 | C0232466 | |
| Disease | osteoarthritis, knee | 1.87e-04 | 158 | 21 | 3 | EFO_0004616 | |
| Disease | social communication impairment | 2.36e-04 | 32 | 21 | 2 | EFO_0005427 | |
| Disease | atrophic macular degeneration, age-related macular degeneration, wet macular degeneration | 8.33e-04 | 60 | 21 | 2 | EFO_0001365, EFO_0004683, EFO_1001492 | |
| Disease | leucine measurement | 1.23e-03 | 73 | 21 | 2 | EFO_0009770 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| PCEGEGGFGLHKKKD | 1466 | O94986 | |
| DREGCGKGKLEDGDG | 141 | O43310 | |
| KGQCFCDGAKGEKGE | 36 | Q01955 | |
| CDGAKGEKGEKGFPG | 41 | Q01955 | |
| EGAKLECGGKGLGRK | 381 | O94788 | |
| GDAKGQKDSCKGDSG | 201 | P49863 | |
| KKGGGEGGAGADEEK | 271 | P08476 | |
| DKGECGSGGGDSKDK | 801 | P42263 | |
| AGGEEKKGAGEGGKD | 151 | P55316 | |
| DGKGNGEDGKEKGED | 181 | P82970 | |
| DDGGFVEKKRGKCGE | 36 | P61583 | |
| DDGGFVEKKRGKCGE | 36 | P61582 | |
| DDGGFVEKKRGKCGE | 36 | P61581 | |
| DGAKGDKGDAGEPGC | 46 | B2RNN3 | |
| KGEKGEQGEDGKAEG | 1326 | Q8IZC6 | |
| CAGEKEGGKDACAGD | 631 | P48740 | |
| MNGGKECDGGDKEGG | 1 | Q9P267 | |
| YKEGGKDACKGDSGG | 566 | P03952 | |
| GERGVKGACGLDGEK | 2626 | Q02388 | |
| KGACGLDGEKGDKGE | 2631 | Q02388 | |
| KGCCGDSGERGGKGQ | 241 | A6NHN0 | |
| GLKGGKKGECAVGAS | 1176 | Q10571 | |
| DDGGFVEKKRGKCGE | 36 | P61580 | |
| GDGKGDKDGEDKGTK | 111 | Q16280 | |
| CKNGGGVGGGELDKK | 231 | Q9H7S9 | |
| GFEEGKKDACKGDSG | 216 | Q9BQR3 | |
| GDEDLTKEKGHGGCG | 171 | P24928 |